Geron (Nasdaq: GERN) granted stock options to five new employees on May 15, 2026, as inducement awards under Nasdaq Listing Rule 5635(c)(4). The options cover an aggregate 333,750 shares at an exercise price of $1.29 per share, with a ten-year term and four-year vesting.
Loading...
Loading translation...
AI-generated analysis. Not financial advice.
Positive
None.
Negative
None.
News Market Reaction – GERN
-0.81%
1 alert
-0.81%News Effect
On the day this news was published, GERN declined 0.81%, reflecting a mild negative market reaction.
Inducement option grant:333,750 sharesNumber of new hires:5 employeesExercise price:$1.29 per share+5 more
8 metrics
Inducement option grant333,750 sharesAggregate stock options granted to five new employees
Number of new hires5 employeesRecipients of inducement stock option grants
Exercise price$1.29 per shareEqual to GERN closing price on May 15, 2026 grant date
Option term10 yearsTerm of inducement stock options
Initial vesting cliff12.5% at 6 monthsVests on six‑month employment anniversary
Remaining vesting period42 monthsBalance vests in equal installments over 42 months
Plan year2018Geron’s 2018 Inducement Award Plan governing these grants
Pre-news price change-7.86%GERN move over prior 24 hours before this article
Market Reality Check
Price:$1.2600Vol:Volume 14,045,552 is belo...
normal vol
$1.2600Last Close
VolumeVolume 14,045,552 is below the 20-day average of 16,296,267 (relative volume 0.86x).normal
TechnicalShares trade below the 200-day MA of 1.41, with the price at 1.295 before this news.
Peers on Argus
GERN was down about 7.86% while peers like AVXL, IMNM, QURE, TSHA and ZBIO also ...
GERN was down about 7.86% while peers like AVXL, IMNM, QURE, TSHA and ZBIO also traded lower, but no names appeared in the momentum scanner, indicating more stock-specific pressure than a coordinated sector move.
Prior inducement stock option grants totaling 855,000 shares to new hires.
Pattern Detected
Recent news often saw price moves diverge from seemingly positive or neutral headlines, with more divergences than alignments.
Recent Company History
Over recent months, Geron has highlighted commercial and clinical progress around RYTELO, including real-world LR-MDS data with 37.5% achieving ≥8-week transfusion independence and Q1 2026 revenue of $51.8M. Earnings and conference announcements in April–May showed mixed price reactions, often diverging from supportive updates and guidance. Prior inducement grants on April 17, 2026 also coincided with a negative move. Today’s option grants fit this pattern of routine corporate actions alongside volatile trading.
Market Pulse Summary
This announcement details standard Nasdaq Rule 5635(c)(4) inducement option grants: 333,750 shares a...
Analysis
This announcement details standard Nasdaq Rule 5635(c)(4) inducement option grants: 333,750 shares at a $1.29 exercise price, 10‑year term and four‑year vesting, used to recruit five new employees. It follows a series of material updates on RYTELO revenues, clinical data, loan facilities, and workforce restructuring. Investors monitoring Geron may focus more on revenue growth, cash levels, clinical readouts and any further equity awards or leadership changes disclosed in future filings and press releases.
"it granted stock options to purchase an aggregate of 333,750 shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise pricefinancial
"The stock options have an exercise price of $1.29 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestfinancial
"and vest over four years, with 12.5% of the shares underlying the options vesting"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
inducement award planfinancial
"subject to the terms and conditions of Geron’s 2018 Inducement Award Plan"
An inducement award plan is a package of pay, often including stock options or restricted shares, granted to a new employee or executive to attract them to join a company — think of it like a signing bonus paid partly in company stock. Investors care because these awards increase compensation expense and can dilute existing shareholders’ ownership, affecting earnings per share and incentives that shape company strategy.
AI-generated analysis. Not financial advice.
FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock options to purchase an aggregate of 333,750 shares of common stock to five newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.
The stock options have an exercise price of $1.29 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.
The equity awards were granted by the Compensation Committee of Geron’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of Geron’s 2018 Inducement Award Plan and the form of stock option agreement under the plan.
About Geron Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.
CONTACT: Dawn Schottlandt Senior Vice President, Investor Relations and Corporate Affairs dschottlandt@geron.com
FAQ
What stock options did Geron (GERN) grant on May 15, 2026?
Geron granted stock options for an aggregate 333,750 common shares to five newly hired employees. According to Geron, these options are inducement awards tied to employment acceptance and were approved by the board’s Compensation Committee under the company’s 2018 Inducement Award Plan.
What is the exercise price of the new Geron (GERN) inducement stock options?
The exercise price of the new Geron inducement stock options is $1.29 per share. According to Geron, this price equals the closing market price of Geron’s common stock on the May 15, 2026 grant date, aligning the awards with prevailing trading levels.
How do the Geron (GERN) inducement stock options vest for new employees?
Geron’s inducement stock options vest over four years for the new employees. According to Geron, 12.5% vests six months after employment start, with the remaining shares vesting in equal monthly installments over the following 42 months, subject to continued employment through each vesting date.
What is the term of the Geron (GERN) inducement stock options granted in May 2026?
The Geron inducement stock options granted in May 2026 have a ten-year term. According to Geron, employees may exercise the options at $1.29 per share during this period, subject to the vesting schedule and other terms in the 2018 Inducement Award Plan and option agreements.
Why were the May 15, 2026 Geron (GERN) stock options classified as inducement grants?
The May 15, 2026 Geron stock options were classified as inducement grants to support new hires’ employment decisions. According to Geron, these awards were granted as a material inducement to accept employment, consistent with Nasdaq Listing Rule 5635(c)(4) requirements for inducement equity awards.
Under which plan and rules were Geron’s May 2026 inducement options granted?
Geron’s May 2026 inducement options were granted under the 2018 Inducement Award Plan. According to Geron, the Compensation Committee approved the grants in accordance with Nasdaq Listing Rule 5635(c)(4), and the awards are governed by the plan’s standard form of stock option agreement.
